---
title: "Milestone (MIST) Q1 2026 Earnings Transcript"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288293396.md"
description: "Milestone Pharmaceuticals reported Q1 2026 results, marking the first commercial quarter for CARDAMYST with $0.2 million in revenue and ~600 prescriptions. The company secured Express Scripts National Formulary listing, covering 25% of commercially insured patients. Operating cash burn was $23.7 million, offset by $75 million from a royalty agreement. Net loss narrowed to $26.1 million. Additionally, Milestone initiated the Phase III ReVeRa-301 trial for AFib-RVR."
datetime: "2026-06-01T14:40:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288293396.md)
  - [en](https://longbridge.com/en/news/288293396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288293396.md)
---

# Milestone (MIST) Q1 2026 Earnings Transcript

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [MIST.US](https://longbridge.com/en/quote/MIST.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)
- [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md)
- [International Paper Q2 2026 Earnings Preview](https://longbridge.com/en/news/294266740.md)
- [Honeywell announces R$ 2.36 per unit dividend for Q3 2026](https://longbridge.com/en/news/294209833.md)